Total Payments
$2,752
2024 Payments
$184.22
Companies
6
Transactions
41
Medicare Patients
2,763
Medicare Billing
$242,062
Payment Breakdown by Category
Food & Beverage$2,733 (99.3%)
Travel$19.08 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,733 | 40 | 99.3% |
| Travel and Lodging | $19.08 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merz North America, Inc. | $1,922 | 16 | $0 (2023) |
| Allergan, Inc. | $565.24 | 18 | $0 (2022) |
| Krystal Biotech Inc | $123.68 | 1 | $0 (2024) |
| ABBVIE INC. | $84.19 | 3 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $44.53 | 2 | $0 (2021) |
| PruGen, Inc. Pharmaceuticals | $12.33 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $184.22 | 3 | Krystal Biotech Inc ($123.68) |
| 2023 | $53.05 | 2 | Merz North America, Inc. ($29.40) |
| 2022 | $153.00 | 6 | Allergan, Inc. ($153.00) |
| 2021 | $316.97 | 2 | MERZ NORTH AMERICA, INC. ($296.80) |
| 2020 | $309.44 | 4 | MERZ NORTH AMERICA, INC. ($297.11) |
| 2019 | $974.03 | 9 | Merz North America, Inc. ($935.84) |
| 2018 | $600.75 | 12 | Allergan Inc. ($398.41) |
| 2017 | $160.15 | 3 | MERZ NORTH AMERICA, INC. ($160.15) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $29.32 | General |
| 04/23/2024 | Krystal Biotech Inc | VYJUVEK (Drug) | Food and Beverage | In-kind items and services | $123.68 | General |
| Category: DERMATOLOGY | ||||||
| 01/18/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $31.22 | General |
| 08/30/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $23.65 | General |
| 08/22/2023 | Merz North America, Inc. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $29.40 | General |
| Category: Dermatology | ||||||
| 06/20/2022 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $130.89 | General |
| 05/12/2022 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $6.61 | General |
| 05/03/2022 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $2.54 | General |
| 05/03/2022 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $1.43 | General |
| 02/23/2022 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $8.56 | General |
| Category: FACIAL AESTHETICS | ||||||
| 02/23/2022 | Allergan, Inc. | — | Food and Beverage | In-kind items and services | $2.97 | General |
| 10/07/2021 | MERZ NORTH AMERICA, INC. | Xeomin (Biological) | Food and Beverage | In-kind items and services | $296.80 | General |
| Category: Dermatology | ||||||
| 09/03/2021 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: IMMUNOLOGY | ||||||
| 07/21/2020 | PruGen, Inc. Pharmaceuticals | — | Food and Beverage | In-kind items and services | $12.33 | General |
| 02/24/2020 | MERZ NORTH AMERICA, INC. | XEOMIN (Biological) | Food and Beverage | Cash or cash equivalent | $116.12 | General |
| Category: DERMATOLOGY | ||||||
| 02/12/2020 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | Cash or cash equivalent | $144.15 | General |
| 02/10/2020 | MERZ NORTH AMERICA, INC. | — | Food and Beverage | Cash or cash equivalent | $36.84 | General |
| 12/13/2019 | Merz North America, Inc. | XEOMIN (Biological), ASCLERA | Food and Beverage | Cash or cash equivalent | $274.60 | General |
| Category: DERMATOLOGY | ||||||
| 12/12/2019 | Merz North America, Inc. | — | Food and Beverage | Cash or cash equivalent | $184.24 | General |
| 12/09/2019 | Merz North America, Inc. | — | Food and Beverage | Cash or cash equivalent | $144.15 | General |
| 11/12/2019 | Merz North America, Inc. | XEOMIN (Biological), ASCLERA | Food and Beverage | Cash or cash equivalent | $86.67 | General |
| Category: DERMATOLOGY | ||||||
| 11/12/2019 | Merz North America, Inc. | XEOMIN (Biological), ASCLERA | Food and Beverage | Cash or cash equivalent | $25.10 | General |
| Category: DERMATOLOGY | ||||||
| 07/31/2019 | Novartis Pharmaceuticals Corporation | COSENTYX (Biological) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: DERMATOLOGY | ||||||
| 05/22/2019 | Merz North America, Inc. | — | Food and Beverage | Cash or cash equivalent | $35.76 | General |
| 03/26/2019 | Merz North America, Inc. | XEOMIN (Biological), ASCLERA | Food and Beverage | Cash or cash equivalent | $185.32 | General |
| Category: DERMATOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 565 | 797 | $96,375 | $49,333 |
| 2022 | 8 | 730 | 1,077 | $128,863 | $67,340 |
| 2021 | 7 | 722 | 1,088 | $119,383 | $64,594 |
| 2020 | 8 | 746 | 1,102 | $121,908 | $60,796 |
Total Patients
2,763
Total Services
4,064
Medicare Billing
$242,062
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 179 | 226 | $38,420 | $22,048 | 57.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 144 | 165 | $23,100 | $11,010 | 47.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 59 | 63 | $11,340 | $5,788 | 51.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 69 | 91 | $9,555 | $4,130 | 43.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 46 | 53 | $7,950 | $4,013 | 50.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 29 | 29 | $2,610 | $1,387 | 53.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 39 | 170 | $3,400 | $956.02 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 203 | 284 | $46,370 | $27,715 | 59.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 180 | 231 | $29,720 | $15,694 | 52.8% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 81 | 102 | $18,360 | $8,724 | 47.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 80 | 93 | $13,950 | $6,740 | 48.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 87 | 112 | $11,745 | $4,954 | 42.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 35 | 39 | $2,990 | $1,635 | 54.7% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 52 | 200 | $4,208 | $1,165 | 27.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 12 | 16 | $1,520 | $712.90 | 46.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 186 | 251 | $40,160 | $24,229 | 60.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 195 | 238 | $26,160 | $15,757 | 60.2% |
| 17110 | Destruction of up to 14 skin growths | Office | 2021 | 105 | 133 | $23,940 | $12,078 | 50.5% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 61 | 69 | $10,350 | $5,469 | 52.8% |
| 17000 | Destruction of skin growth | Office | 2021 | 81 | 102 | $10,695 | $3,990 | 37.3% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 37 | 41 | $2,870 | $1,740 | 60.6% |
| 17003 | Destruction of 2-14 skin growths | Office | 2021 | 57 | 254 | $5,208 | $1,331 | 25.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 261 | 343 | $54,550 | $28,428 | 52.1% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 96 | 120 | $19,360 | $10,703 | 55.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 143 | 174 | $19,140 | $9,463 | 49.4% |
About Dr. Franziska Ringpfeil, MD
Dr. Franziska Ringpfeil, MD is a Pediatric Dermatology healthcare provider based in Haverford, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1760471619.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Franziska Ringpfeil, MD has received a total of $2,752 in payments from pharmaceutical and medical device companies, with $184.22 received in 2024. These payments were reported across 41 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($2,733).
As a Medicare-enrolled provider, Ringpfeil has provided services to 2,763 Medicare beneficiaries, totaling 4,064 services with total Medicare billing of $242,062. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatric Dermatology
- Other Specialties Dermatology, Procedural Dermatology
- Location Haverford, PA
- Active Since 10/13/2005
- Last Updated 02/01/2010
- Taxonomy Code 207NP0225X
- Entity Type Individual
- NPI Number 1760471619
Products in Payments
- XEOMIN (Biological) $687.81
- Xeomin (Biological) $326.20
- VYJUVEK (Drug) $123.68
- COSENTYX (Biological) $44.53
- BOTOX COSMETIC (Biological) $22.17
- BOTOX (Biological) $8.56
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.